The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.
Current guidelines suggest that polycythemia vera (PV) patients maintain a strict hematocrit less than 45%. However, to date, little is known about the relationship between HCT control and PV- related symptom burden. In this study, PV patient data was analyzed from the CYTO PV trial (n = 224) and the MPN-SAF study cohort (n = 645). No significant differences in symptom burden were seen at the 6 and 12 month follow-up when evaluating prospective hematocrit control in the CYTO PV cohort. Patients in the MPN-SAF cohort with a worst item score of greater than 5/10 on the Myeloproliferative Neoplasm Symptom Total Symptom Score had a significantly lower mean hematocrit (p = .0376). These findings suggest a relationship between traditional aggressive therapy for PV and increased symptom burden with prolonged therapy. Thus, symptom burden should be considered when contemplating the choice of therapy in the second-line setting for PV.
a Department of Hematology and Oncology , Mayo Clinic , Scottsdale , AZ , USA.|b Department of Hematology and Oncology , Oregon Health and Science University , Portland , OR , USA.
Robyn Marie
RM
Scherber
c Department of Internal Medicine , Mayo Clinic , Scottsdale , AZ , USA.
Holly Lynn
HL
Geyer
d Department of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.
Amylou C
AC
Dueck
d Department of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.
Heidi E
HE
Kosiorek
e Unit of Hematology, Ospedale Papa Giovanni XXIII , Foundation for Research (FROM) , Bergamo , Italy.
Guido
G
Finazzi
f Consorzio Mario Negri Sud , Santa Maria Imbaro (CH), Italy.
Riccardo
R
Cavazzina
g Istituto Mario Negri Sud , S. Maria Imbaro , Italy.
Arianna
A
Masciulli
g Istituto Mario Negri Sud , S. Maria Imbaro , Italy.
Marco
M
Scarano
h Section of Hematology , University of Florence , Florence , Italy.
Alessandro M
AM
Vannucchi
a Department of Hematology and Oncology , Mayo Clinic , Scottsdale , AZ , USA.
Ruben A
RA
Mesa
e Unit of Hematology, Ospedale Papa Giovanni XXIII , Foundation for Research (FROM) , Bergamo , Italy.
Tiziano
T
Barbui
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D006400:Hematocrit; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D018962:Phlebotomy; D011087:Polycythemia Vera / Q000097:blood* / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D063189:Symptom Assessment
Symptom burden; phlebotomy; polycythemia vera; quality of life